Floatz logo

Lenalidomide

Post-Transplant Lymphoproliferative Disease

Northwestern UniversitySmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Post-Transplant Lymphoproliferative Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Washington University School of Medicine
Phase 2BBB
Rituximab
Jennifer Amengual
Phase 2BB
Fludarabine
City of Hope Medical Center
Phase 2BB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB
Methotrexate
National Cancer Institute (NCI)
Phase 2BB

View all 47 →

Same molecule, other indications

Lenalidomide is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
74 / 100
View asset →
plasma cell neoplasmActive
BBB
Indicative · Phase 3
72 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →